Financial Data and Key Metrics Changes - Total revenue for Q4 2022 was $953.3 million, with non-GAAP earnings per share at $0.82, exceeding guidance [10][44] - For the full year, the company utilized $542 million of cash flow to repurchase 7.7 million shares, reflecting confidence in future performance [10][55] - Gross margin for Q4 was 62.5%, and operating margin was 27.9%, both ahead of previous estimates [52][44] Business Line Data and Key Metrics Changes - Diagnostics revenue was $520.9 million, a decline of 35.6% year-over-year, but organic diagnostics revenue increased by 11% when excluding COVID assay revenue [45][46] - Molecular diagnostics grew over 17% in Q4, driven by increased assay utilization through the expanded Panther installed base [19][47] - Surgical revenue grew over 11% in Q4, with nearly 9% growth excluding the Boulder acquisition [49][50] - Breast Health revenue was down 16% due to chip shortages, but recovery is expected in 2023 [22][49] Market Data and Key Metrics Changes - International business grew over 6% organically in 2022, now accounting for nearly 30% of total revenue [35] - The company expects low double-digit growth across all divisions in fiscal 2023, including international markets [25][36] Company Strategy and Development Direction - The company aims to be a champion for women's health, focusing on expanding its core franchises in diagnostics, surgical, and breast health [17][18] - Strategic investments are being made to enhance growth drivers across all divisions, with a focus on innovation and patient access [37][38] - The company is committed to maintaining a strong balance sheet and leveraging its cash flow for strategic acquisitions [54][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to thrive despite macroeconomic challenges, citing a transformation during the pandemic [15][16] - The company anticipates a rebound in Breast Health as chip supply normalizes, with expectations for low double-digit growth in 2023 [32][63] - Management highlighted the importance of maintaining strong financial results while continuing to invest in women's health initiatives [17][37] Other Important Information - The company expects COVID assay sales to be $75 million in Q1 2023 and $150 million for the full year, indicating a continued role for COVID testing in the business [66] - The company has a robust cash position of $2.3 billion and a low leverage ratio of 0.2 times, providing flexibility for future investments [53][54] Q&A Session Summary Question: Insights on Breast Health and chip supply visibility - Management noted that customers are likely to remain loyal due to the superiority of their products, and they are optimistic about improving chip supply visibility [77][80] Question: Operating margin expectations - Management indicated that operating margins are expected to remain around 30% throughout the year, with variations based on COVID and Breast Health recovery dynamics [84] Question: COVID testing visibility and future contributions - Management stated that while it is difficult to predict COVID testing patterns, they believe it will remain a significant part of their business moving forward [101][102] Question: Molecular testing dynamics and customer utilization - Management highlighted strong growth in molecular diagnostics and noted that new customers are increasingly utilizing non-COVID assays [110][111] Question: Long-term growth expectations - Management reaffirmed a long-term growth expectation of 5% to 7%, while anticipating above-average growth in the near term [117][118]

Hologic, Inc. (NASDAQ:HOLX) Q3 2022 Results Earnings Conference Call July 28, 2022 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Tejas Savant - Morgan Stanley Patrick Donnelly - Citigroup Nisarg Shah - Bank of America Merrill Lynch Vijay Kumar - Evercore ISI Joseph Conway - Needham & Company Puneet Souda - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 25, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOGIC, ...

Hologic, Inc. (NASDAQ:HOLX) Q2 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Steve MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Puneet Souda - SVB Securities Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Derik de Bruin - Bank of America Ryan Zimmerman - B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 26, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOGIC ...

| --- | --- | --- | |---------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Growing Stronger by Delivering on Our Purpose, Passion and Promise | | | | February 2022 | | | Safe Harbor Statement 2 This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other info ...

Hologic, Inc. (NASDAQ:HOLX) Q1 2022 Earnings Conference Call February 2, 2022 4:30 PM ET Corporate Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Dan Leonard - Wells Fargo Vijay Kumar - Evercore ISI Jack Meehan - Nephron Research Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Brian Weinstein - William Blair Casey Woodring - JPMorgan Derik De Bruin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 25, 2021 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLO ...

| --- | --- | --- | |-----------------------------------------------------------------------|-------|-------| | | | | | | | | | A Different, Stronger Company Making a Unique Difference in the World | | | | Steve MacMillan Chairman, President & CEO | | | | 40th Annual J.P. Morgan Healthcare Conference | | | Safe Harbor Statement 2 This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intention ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 25, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 _________________________________________________ ...